Verano Holdings (VRNO) Net Income towards Common Stockholders (2021 - 2026)
Verano Holdings (VRNO) reported Net Income towards Common Stockholders of -$17.8 million for Q1 2026, down 54.78% year-over-year from -$39.4 million in Q1 2025, and up 90.28% quarter-over-quarter from -$183.4 million in Q4 2025.
Verano Holdings (VRNO) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends
Verano Holdings (VRNO) has 6 years of Net Income towards Common Stockholders data on file, last reported at -$17.8 million in Q1 2026.
- Net Income towards Common Stockholders for Q1 2026 came in at -$17.8 million, down 54.78% year-over-year; the trailing twelve-month figure through Mar 2026 was -$264.2 million (up 24.2% YoY), and the FY2025 annual result was -$257.9 million, up 24.56% from the prior year.
- Net Income towards Common Stockholders climbed to -$17.8 million in Q1 2026 per VRNO's latest filing, from -$183.4 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $45.9 million in Q1 2022 and troughed at -$272.7 million in Q4 2024.
- A 5-year average of -$56.4 million and a median of -$19.2 million in 2025 frame the typical range for Net Income towards Common Stockholders.
- On a YoY basis, Net Income towards Common Stockholders climbed as much as 66.72% in 2022 and fell as far as 3065.98% in 2022.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$216.1 million in 2022, then soared by 64.24% to -$77.3 million in 2023, then plunged by 252.85% to -$272.7 million in 2024, then jumped by 32.74% to -$183.4 million in 2025, then soared by 90.28% to -$17.8 million in 2026.
- Business Quant data shows VRNO's Net Income towards Common Stockholders at -$17.8 million in Q1 2026, -$183.4 million in Q4 2025, and -$43.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn | 366.00 Mn |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn | 601.00 Mn |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn | 274.90 Mn |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn | 1.99 Mn |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn | 197.90 Mn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn | -66.53 Mn |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn | 118.42 Mn |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn | -92.12 Mn |
| 10 | Verano Holdings | - | - | 98.98 Mn | -17.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.82 Mn |
| Dec 31, 2025 | -183.41 Mn |
| Sep 30, 2025 | -43.83 Mn |
| Jun 30, 2025 | -19.15 Mn |
| Mar 31, 2025 | -11.52 Mn |
| Dec 31, 2024 | -272.71 Mn |
| Sep 30, 2024 | -42.57 Mn |
| Jun 30, 2024 | -21.76 Mn |
| Mar 31, 2024 | -4.82 Mn |
| Dec 31, 2023 | -77.29 Mn |
| Sep 30, 2023 | -17.76 Mn |
| Jun 30, 2023 | -13.06 Mn |
| Mar 31, 2023 | -9.24 Mn |
| Dec 31, 2022 | -216.11 Mn |
| Sep 30, 2022 | -42.99 Mn |
| Jun 30, 2022 | -9.85 Mn |
| Mar 31, 2022 | 45.87 Mn |
| Dec 31, 2021 | -6.83 Mn |
| Sep 30, 2021 | -11.96 Mn |
| Jun 30, 2021 | -29.59 Mn |